Abstract:Background: Patients with inflammatory bowel disease (IBD) are susceptible to viral infection, which may include SARS-CoV-2. The management of IBD and COVID-19 can be challenging, as the majority of patients are on some immunosuppressive medications. The aim of this study is to identify practice patterns, management strategy, and outcomes of IBD and COVID-19 with a world-wide survey of health care providers. Methods: The 22-item survey questionnaires were sent to the IBD community worldwide, including health care providers of IBD from epicenter countries at different time points, such as China, the United States, and Spain. Fifty IBD clinicians outside China were invited for the survey. The survey was sent to members of China Crohn’s and Colitis Foundation as a web blast.Results: Of 192 respondents (39 from outside China, 153 from China), 95 (49.5%) were IBD specialists or IBD colorectal surgeons. Thirty clinicians (15.6%) reported encountering COVID-19 patients during the pandemic, including 18 (9.4%) and 12 (5.2%) who cared for Crohn’s disease (CD) patients and ulcerative colitis (UC) patients with COVID-19, respectively. A majority of clinicians (N=152, 79.2%) believed that screening for SARS-CoV-2 was henceforth necessary before the initiation of biological therapy. Forty-two (21.9%) clinicians reported that they have switched infused biologics to an injectable biologic during the outbreak. Since the outbreak, 77 (40.1%) clinicians initiated systemic corticosteroids; 78 (40.6%) initiated immunomodulators; and 120 (62.5%) initiated biologics. Most clinicians [120/181 (66.3%)] recommended the continuation of corticosteroids or immunomodulators in all their IBD patients. Seventy-nine clinicians (43.6%) continued biologics in all their patients during the pandemic. One hundred and forty-seven (81.2%) respondents reported IBD flare-up of at least some of their patients and 106 reported IBD flare-up after continuation of immunosuppressive medications (ISM) (i.e. corticosteroids, immunomodulators, or biologics). One hundred and six (52.1%) reported disease progression of their IBD patients (i.e. IBD-related emergency room visit, hospitalization, or surgery) while continuing ISM; and 92 (47.9%) reported disease progression of IBD after discontinuing ISMs. Further analysis showed that continuation of ISMs or initiation of biologics during the pandemic were not associated with the increased number of patients with disease flare-up or progression. Of the 30 clinicians encountering COVID-19, 13 (43.3%) reported that their patients were not on corticosteroids; 14 (46.6%) reported that none of their patients were on immunomodulators; 13 (43.3%) reported that none of their patients was on any biologics. Three clinician reported COVID-19-associated deaths.Conclusions: Continued use of ISM was common in IBD clinicians during the outbreak. IBD patients can develop COVID-19 in the absence of the use of ISM. More than half of surveyed clinicians continued biologics and even initiated therapy during the pandemic. On the other hand, one third to close to one half of clinicians discontinued ISMs and none of them noticed any of their patients with disease flare or progression. The majority of clinicians recommended future screening for SARS-CoV-2 before the initiation of biological therapy.Funding Statement: None.Declaration of Interests: Dr. Yan Chen: None. Dr. Song Xu: None. Dr. Garrett Lawlor: Research grants for IBD fellowship from Janssen and Abbvie. Dr. Charles Bernstein: Has served on advisory boards for Abbvie Canada, Roche Canada, Janssen Canada, Takeda Canada, Pfizer Canada, consulted to Mylan Pharmaceuticals, has received educational grants from Abbvie Canada, Pfizer Canada, Takeda Canada, and Janssen Canada and has been on the speaker’s panel for Janssen Canada, Abbvie Canada, Medtronic Canada, and Takeda Canada. Dr. Francis A. Farraye: Consultant for BMS, Braintree Labs, Gilead, GSK, Innovation Pharmaceuticals, Janssen, Pfizer and Sebela. He sits on a DSMB for Lilly and Theravance. Dr. Marietta Iacucci: Research grant from Pentax, Olympus and Fujifilm. Consultant and speaker for Pentax, Abbvie and Jansen. Dr. Joseph Picoraro: No disclosure. Dr. Cindy Zhu: No financial conflicts of interest. Dr. Ravi P. Kiran: No disclosures. Dr. Bo Shen: consultant and speaker for Abbvie, Janssen, and Takeda,Ethics Approval Statement: The central institutional review board of study was approved by the ethics committee of the 2nd Hospital of Zhejiang University.

COVID-19 advocacy bias in the BMJ: meta-research evaluation

Zero-covid advocacy during the COVID-19 pandemic: a case study of views on Twitter/X

Open science and conflict of interest policies of medical and health sciences journals before and during the COVID-19 pandemic: A repeat cross-sectional study

Gender disparity between authors in leading medical journals during the COVID-19 pandemic: a cross-sectional review

Scientific quality of COVID-19 and SARS CoV-2 publications in the highest impact medical journals during the early phase of the pandemic: A case control study

COVID-19-related medical research: a meta-research and critical appraisal

How COVID-19 Affected the Journal Impact Factor of High Impact Medical Journals: Bibliometric Analysis

The private versus public contribution to the biomedical literature during the COVID-19, Ebola, H1N1, and Zika public health emergencies

Practice Patterns of Medical Management of Inflammatory Bowel Disease During Pandemic of COVID-19: A Global Survey of Health Care Providers

Media Bias Matters: Understanding the Impact of Politically Biased News on Vaccine Attitudes in Social Media

A synthesis of evidence for policy from behavioural science during COVID-19

Impact of the COVID-19 pandemic on publication dynamics and non-COVID-19 research production

Problems with evidence assessment in COVID-19 health policy impact evaluation: a systematic review of study design and evidence strength

MP Twitter Abuse in the Age of COVID-19: White Paper

The impact of the COVID pandemic on publication disciplines among major general medical journals: A bibliometric analysis using natural language processing and traditional statistics

Biased, wrong and counterfeited evidences published during the COVID-19 pandemic, a systematic review of retracted COVID-19 papers

Gender imbalance in gynecologic oncology authorship and impact of COVID-19 pandemic

Evidence-based medicine and COVID-19: what to believe and when to change

Deceptive tactics: Misappropriation of scientific literature by 'Gazeta do Povo' in undermining COVID-19 vaccination efforts

Panel stacking is a threat to consensus statement validity

Evaluating Trends in COVID-19 Research Activity in Early 2020: The Creation and Utilization of a Novel Open-Access Database